AstraZeneca signs strategic partnership with Beijing; invests $2.5bn
The pharmaceutical firm expects its workforce in Beijing to grow to 1,700 employees and is launching a JV with BioKangtai to help make vaccines; there is also investment into AI.
UK and Swedish pharmaceutical giant AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic research & development (R&D) centre, according to a March 21 announcement.
Sign-in to access CorporateTreasurer content.
Please sign in to your subscription to unlock full access to our premium CT resources.
Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial. Click the link to get started.
Note: This free trial is a one-time offer. You are eligible for one free trial per year.
If you are a treasurer, CFO or senior finance professional at a corporate, please register to the website here.
Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.
© Haymarket Media Limited. All rights reserved.
Top news, insights and analysis every Tuesday & Thursday
Free registration gives you access to our email newsletters
for unlimited access to all articles, newsletters
